Chromocell Therapeutics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for CHRO.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

According to 1 stock analyst, the rating for CHRO is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24
Strong Buy	1	1
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
James Molloy Alliance Global Partners	Alliance Global Partners	Strong Buy Initiates n/a	Strong Buy	Initiates	n/a	n/a	Jun 18, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.33

from -5.78

EPS Next Year

-1.12

from -1.33

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	199.93K	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-	-	-5.65	-5.78	-1.33	-1.12	-1.07
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.